April 5, 2012

Merial expands US business with Newport Laboratories acquisition

Merial, the animal health division of Sanofi, has acquired Newport Laboratories, enlarging Merial's presence in the swine production market with autogenous vaccines.

Newport Laboratories is the leader in autogenous vaccines with a focus on swine and bovine production markets, while Merial has been a long-standing leader in vaccine technology with recombinant-vectored vaccines for large animals and pets.

The acquisition will enable Merial to expand its production animal business in the US and optimise Merial's product technology with Newport's demand realisation expertise, thus providing a unique opportunity to meet the needs of US swine producers.

He adds, "The combination of Newport's expertise and Merial's strength intechnology and geographic footprint will reinforce our exposure to the swine market segment and illustrates our strategy to expand our position in treatments for production animals".

Newport Laboratories will continue to operate from its Worthington site.